- Home
- HIMX vs ETNB Comparison
HIMX vs ETNB Comparison
Compare HIMX & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIMX
- ETNB
- Stock Information
- Founded
- HIMX 2001
- ETNB 2018
- Country
- HIMX Taiwan
- ETNB United States
- Employees
- HIMX N/A
- ETNB N/A
- Industry
- HIMX Semiconductors
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- HIMX Technology
- ETNB Health Care
- Exchange
- HIMX Nasdaq
- ETNB Nasdaq
- Market Cap
- HIMX 1.1B
- ETNB 1.0B
- IPO Year
- HIMX 2006
- ETNB 2019
- Fundamental
- Price
- HIMX $7.60
- ETNB $7.70
- Analyst Decision
- HIMX Buy
- ETNB Strong Buy
- Analyst Count
- HIMX 1
- ETNB 9
- Target Price
- HIMX $15.00
- ETNB $27.25
- AVG Volume (30 Days)
- HIMX 1.1M
- ETNB 1.5M
- Earning Date
- HIMX 05-08-2025
- ETNB 05-01-2025
- Dividend Yield
- HIMX 3.82%
- ETNB N/A
- EPS Growth
- HIMX 87.51
- ETNB N/A
- EPS
- HIMX 0.50
- ETNB N/A
- Revenue
- HIMX $914,385,000.00
- ETNB N/A
- Revenue This Year
- HIMX $6.46
- ETNB N/A
- Revenue Next Year
- HIMX $12.70
- ETNB N/A
- P/E Ratio
- HIMX $15.18
- ETNB N/A
- Revenue Growth
- HIMX 0.62
- ETNB N/A
- 52 Week Low
- HIMX $5.12
- ETNB $4.16
- 52 Week High
- HIMX $13.91
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- HIMX 56.35
- ETNB 53.47
- Support Level
- HIMX $7.31
- ETNB $7.40
- Resistance Level
- HIMX $7.82
- ETNB $8.92
- Average True Range (ATR)
- HIMX 0.27
- ETNB 0.54
- MACD
- HIMX 0.16
- ETNB 0.13
- Stochastic Oscillator
- HIMX 85.71
- ETNB 53.88
About HIMX Himax Technologies Inc.
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).